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ABSTRACT
The MYC transcription factor coordinates, via different RNA polymerases, the 
transcription of both ribosomal RNA (rRNA) and protein genes necessary for nucleolar 
as well as mitochondrial ribogenesis. In this study we tested if MYC-coordination of 
rRNA transcription in the nucleolus and in the mitochondrion drives (cancer) cell 
proliferation. Here we show that the anti-proliferative effect of CX-5461, a Pol I 
inhibitor of rRNA transcription, in ovarian (cancer) cell contexts characterized by 
MYC overexpression is enhanced either by 2’-C-Methyl Adenosine (2’-C-MeA), a 
ribonucleoside that inhibits POLRMT mitochondrial rRNA (mt-rRNA) transcription 
and doxycycline, a tetracycline known to affect mitochondrial translation. Thus, 
hindering not only mt-rRNA transcription, but also mitoribosome function in MYC-
overexpressing ovarian (cancer) cells, potentiates the antiproliferative effect of 
CX-5461. Targeting MYC-regulated rRNA transcription and ribogenesis in both the 
nucleolus and mitochondrion seems to be a novel approach worth of consideration 
for treating MYC-driven cancer.
INTRODUCTION
The nucleolus is the major site of ribosomal RNA 
(rRNA) synthesis. Moreover, the mitochondrion is another 
site of rRNA synthesis. The MYC transcription factor 
regulates genes encoding proteins necessary for both 
nucleolar and mitochondrial rRNA transcription. MYC 
enables RNA Polymerase I (Pol I)-mediated nucleolar 
rRNA transcription by binding directly the rDNA 
promoter to induce chromatin modifications that enhance 
Pol I accessibility and facilitate the assembly of the Pol 
I transcription machinery [1–4]. MYC also controls 
RNA Polymerase II (Pol II)-mediated transcription of 
“Pol I regulon” genes encoding for basal components 
of the Pol I transcription machinery, including RRN3, 
UBTF, the SL1 complex component TAF1C, and the 
Pol I subunits POLR1B and POLR1E [5, 6]. In this 
way, MYC regulates the availability of nucleolar “Pol I 
regulon” factors necessary to activate rDNA genes [6]. 
As far as mitochondrial rRNA transcription is concerned, 
MYC regulates, via Pol II, the transcription of both the 
mitochondrial RNA polymerase POLRMT [7] and the 
mitochondrial transcription factor TFAM [8]. Both 
POLRMT and TFAM are necessary for transcription of 
mitochondrial DNA (mtDNA) into mitochondrial 12S 
and 16S rRNA (mt-rRNA) [9]. Moreover, MYC via Pol II 
controls the transcription of several proteins required for 
mitoribogenesis [10]. Hence the hypothesis that targeting 
both nucleolar and mitochondrial rRNA synthesis 
in MYC-overexpressing cancer can have a potential 
antiproliferative value.
In cancer of different histotypes MYC gene 
amplification or upregulation drive tumorigenesis 
by inducing stemness, promoting cell growth and 
proliferation, and hampering cell differentiation [11, 12]. 
Thus, drugs capable of inhibiting nucleolar Pol I-mediated 
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rRNA transcription are emerging as new tools to target 
MYC-overexpressing cancer [13, 14]. One of these drugs 
is CX-5461. This small molecule, by selectively inhibiting 
Pol I-mediated rRNA transcription, can efficiently curb 
cancer cell proliferation both in vitro and in vivo [15–20]. 
Indeed, recent studies suggest that CX-5461 effectively 
targets MYC-driven proliferation in different cancer cell 
contexts, including lymphoma [16, 21], multiple myeloma 
[22], and prostate cancer [23, 24].
Inhibition of mitochondrial ribogenesis is also a 
promising anti-cancer approach [25, 26]. Mitoribogenesis 
can be hindered by drugs targeting POLRMT-mediated 
mt-rRNA transcription, like 2’C-Methyl-Adenosine 
(2’-C-MeA), as recently reported in acute myelogenous 
leukemia studies [27]. Moreover, due to the conservation 
between bacteria and mitochondria, antibiotics inhibiting 
bacterial protein synthesis (e.g. doxycycline) seem 
capable of inhibiting cancer cell proliferation by targeting 
mitochondrial translation [7, 10, 26].
In this study we provide evidence that MYC-
induced rRNA transcription both in the nucleolus and 
mitochondrion concur to promote the proliferation of 
MYC-overexpressing cancer cells. Consistently, MYC 
overexpression sensitizes cells to the antiproliferative 
action of drugs targeting on one hand nucleolar Pol 
I-mediated rRNA transcription (e.g. CX-5461), and on 
the other hand, either POLRMT-mediated mitochondrial 
rRNA transcription (e.g. 2’-C-MeA) or mitoribosome 
function (e.g. doxycycline). Moreover, both 2’-C-MeA 
and doxycycline, when combined with CX-5461, induce 
a more effective antiproliferative action on MYC-
overexpressing cells. Overall, targeting MYC-regulated 
rRNA transcription and ribogenesis in two distinct cell 
sites is an unconventional approach worth of consideration 
for treating MYC-driven cancer.
RESULTS
Evidence of MYC-induced proliferation 
consequent to upregulation of both “Pol I 
regulon” factors and rRNA transcription in 
human HFF fibroblasts
MYC is known to promote nucleolar rRNA 
transcription through direct activation of the Pol I 
transcription machinery [2–4] as well as activation of 
Pol II-mediated transcription of MYC-target genes 
encoding “Pol I regulon” factors, including RRN3, UBTF, 
TAF1C, and the Pol I subunits POLR1B and POLR1E 
[5, 6]. To start to assess the proliferation effects of MYC 
overexpression due to both Pol II-mediated transcription 
of “Pol I regulon” factors and Pol I-mediated rRNA 
transcription, we used a well-characterized model of 
MYC-overexpressing human fibroblasts (HFF-MYC) [3, 
28, 29].
HFF-MYC cells (Figure 1A) express higher 
levels of RRN3, UBF, TAF1C, POLR1B and POLR1E 
mRNAs relative to control HFF (HFF-Ctrl) (Figure 1B). 
Consistently, HFF-MYC also displayed upregulation of 
rRNA transcription, which was assessed by using two 
different strategies: 1) qRT-PCR of the 47S pre-rRNA 
5’ETS, which is spliced out from mature rRNA (Figure 
1C), and 2) quantitative analysis of 5-Ethynyl Uridine 
(EU) incorporation into newly synthesized RNA within 
the B23-positive nucleolar compartment (Figure 1D).
MYC overexpression significantly promoted HFF-
MYC cell proliferation, which was evaluated both by 
both MTT assay (Figure 1E, left) and incorporation of 
5-ethynyl-2′-deoxyuridine (EdU) into nascent DNA of 
cells in S phase (Figure 1E, middle and right). To further 
assess if upregulation of rRNA transcription contributes to 
MYC-induced cell proliferation, we treated cells with the 
Pol I inhibitor CX-5461, which prevents the formation of 
the Pol I pre-initiation complex [17]. Treatment with CX-
5461 (100 nM) significantly counteracted MYC-induced 
rRNA transcription (assessed as pre-rRNA) in HFF-MYC 
cells (Figure 1F, red bars). CX-5461 also counteracted HFF-
MYC proliferation in a dose-dependent manner (Figure 1G, 
left, red bars). To a lesser extent, CX-5461 inhibited rRNA 
transcription (Figure 1F, blue bars) and, consequently, 
proliferation (Figure 1G, left, blue bars) also in the HFF-Ctrl 
normal cell context. However, when HFF-MYC and HFF-
Ctrl proliferation data were normalized to their respective 
untreated controls, HFF-MYC showed significantly higher 
sensitivity to the anti-proliferative action of CX-5461 
relative to normal HFF-Ctrl (Figure 1G, right).
Overall, these preliminary results in a human 
fibroblast cell context indicate that MYC-induced 
proliferation can be traced to increased rRNA transcription 
due to: a) MYC-induced direct activation of Pol I, and 
b) MYC-induced upregulation of “Pol I regulon” factors. 
Moreover, MYC overexpression sensitizes HFF cells to 
the anti-proliferative action of the Pol I inhibitor CX-5461.
Increased proliferation consequent to 
upregulation of both “Pol I regulon” genes and 
rRNA transcription in MYC-overexpressing 
human ovarian epithelial cells
According to The Cancer Genome Atlas, MYC 
amplification/upregulation is frequent in cancer, including 
ovarian cancer, where it is detected in over 30% of cases 
[30]. For this reason, we tested if MYC overexpression in 
ovarian cancer induces Pol I-mediated rRNA transcription 
as well as Pol II-mediated transcription of “Pol I regulon” 
genes. As shown here, CAOV4 ovarian cancer cells, which 
overexpress MYC (Figure 2A), display increased levels of 
rRNA transcription (assessed as pre-rRNA) (Figure 2B) 
and upregulation of “Pol I regulon” genes (Figure 2C) 
relative to CAOV3 ovarian cancer cells, which do not 
overexpress MYC.
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Next, we set out to test the effects of different levels 
of MYC overexpression on nucleolar rRNA transcription 
in IOSE and HOSE human ovarian epithelial cells. Using 
telomerase-immortalized IOSE cells [31] we developed 
cells with increasing expression levels of exogenous 
MYC: IOSE-MYC, with MYC expression higher than 
control IOSE-Ctrl cells, and IOSE-MYC2, with a MYC 
overexpression level higher than IOSE-MYC (Figure 3A). 
The expression of “Pol I regulon” target genes (RRN3, 
UBF, TAF1C, POLR1B, POLR1E) was significantly 
higher in MYC-overexpressing IOSE lines than in 
IOSE-Ctrl, and correlated with MYC level (Figure 3B). 
Figure 1: Evidence of MYC-induced proliferation consequent to upregulation of both “Pol I regulon” factors and 
rRNA transcription in human HFF fibroblasts. (A-B) HFF-MYC fibroblasts overexpressing exogenous MYC (see qRT-PCR in 
A, left, and Western Blot in A, right) express significantly higher levels of “Pol I regulon” genes (assessed by q-RT-PCR) (B) relative to 
HFF-Ctrl fibroblasts. (C-D) HFF-MYC display increased nucleolar rRNA transcription relative to HFF-Ctrl, as measured by qRT-PCR of 
pre-rRNA 5’ETS (C) as well as by immunofluorescent quantification of EU incorporation in the B23-positive nucleolar compartment (D). 
Nucleolar EU incorporation was digitally quantified with Photoshop (see Materials and Methods for details). (E) MTT assay (left) and EdU 
incorporation analysis (middle and right) show that HFF-MYC cells proliferate significantly more than HFF-Ctrl cells. (F-G) Treatment 
with the Pol I inhibitor CX-5461, by reducing nucleolar rRNA transcription (F), inhibits proliferation of HFF-MYC cells significantly more 
than HFF-Ctrl cells (G). The chart in G, left, shows values normalized to untreated HFF-Ctrl; the chart in G, right, shows values normalized 
to each untreated cell line. *p<0.05, **p<0.01, ***p<0.001.
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Moreover, MYC-overexpressing IOSE displayed 
increased rRNA transcription, which was assessed both by 
pre-rRNA qRT-PCR (Figure 3C, left) and nucleolar EU 
incorporation (Figure 3C, middle and right). Consistently, 
we detected a MYC level-dependent increase of cell 
proliferation in IOSE-MYC and IOSE-MYC2 relative to 
IOSE-Ctrl (see MTT assay in Figure 3D, left, and EdU 
incorporation assay in Figure 3D, middle and right). We 
obtained similar findings also in SV40-immortalized 
HOSE cells (Supplementary Figure 1A-1D).
Thus, regardless of the cell context, increasing MYC 
overexpression seems sufficient to differentially foster cell 
proliferation by inducing Pol II-dependent transcription of 
“Pol I regulon” genes as well as Pol I-dependent rRNA 
synthesis.
Additional evidence that upregulation of “Pol 
I regulon” genes contributes to promote cell 
proliferation in MYC-overexpressing IOSE cells
To mechanistically prove that increased proliferation 
of MYC-overexpressing IOSE cells was due, in part, 
to upregulation of “Pol I regulon” genes and rRNA 
transcription, we transiently transfected IOSE-MYC2 cells 
with short interfering RNAs (siRNAs) targeting either 
MYC, or either one of two key components of the “Pol I 
regulon”: RRN3 and UBF.
As shown in Figure 4A, transient MYC knock 
down by siMYC in IOSE-MYC2 cells (left) resulted in 
downregulation of both RRN3 and UBF mRNAs, as well 
as in decreased pre-rRNA level (right) relative to cells 
transfected with control siRNA (siCtrl). Importantly, MYC 
knock down also counteracted MYC-induced proliferation 
of IOSE-MYC2 cells (see EdU incorporation assay in 
Figure 4B). In turn, transient knock down of either RRN3 
(Figure 4C, left) or UBF (Figure 4C, right) in IOSE-
MYC2 was sufficient to significantly reduce both rRNA 
transcription (see pre-rRNA qRT-PCR in Figure 4C, left 
and right), and cell proliferation (see EdU incorporation 
assay in Figure 4D).
Based on these findings, the pro-proliferative effects 
of MYC overexpression in human ovarian epithelial cells 
rely, at least in part, on MYC transcriptional ability to 
upregulate “Pol I regulon” genes.
MYC overexpression sensitizes human ovarian 
epithelial cells to the anti-proliferative action of 
the Pol I inhibitor CX-5461
Selective Pol I inhibitors have been rapidly 
emerging as drugs capable of targeting increased rRNA 
synthesis [19, 32]. Based on preliminary evidence of an 
antiproliferative effect of the Pol I inhibitor CX-5461 in 
MYC-overexpressing HFF (see Figure 1G), we did test 
if MYC-induced rRNA transcription was also capable of 
sensitizing IOSE cells to the anti-proliferative action of 
CX-5461.
As shown in Figure 5A, CX-5461 (100 nM) reduced 
rRNA transcription (assessed by pre-rRNA quantitative 
RT-PCR) significantly more in IOSE-MYC2 relative to 
Figure 2: Evidence that MYC overexpression in ovarian cancer cells is associated with upregulation of rRNA and “Pol 
I regulon” factors. (A-C) Endogenous MYC overexpression in CAOV4 ovarian cancer cells (see Western Blot in A, left, and qRT-PCR 
in A, right) is associated with increased rRNA transcription (assessed by pre-rRNA qRT-PCR) (B) and increased expression of “Pol I 
regulon” genes (assessed by qRT-PCR) (C) relative to CAOV3 ovarian cancer cells, with no MYC overexpression. All differences between 
CAOV4 and CAOV3 are significant (p<0.05).
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IOSE-Ctrl. Consistently, IOSE-MYC2 cells also displayed 
increased sensitivity to the anti-proliferative action of CX-
5461 even at the lowest concentration (Figure 5B). Indeed 
by EdU incorporation we found that at 10 nM, CX-5461 
reduced the number of cells in S phase significantly more 
in IOSE-MYC2 than in IOSE-Ctrl cells (Figure 5C). A 
similar antiproliferative response to CX-5461 was also 
found in HOSE cells (Supplementary Figure 1E).
Overall, these findings indicated that a) upregulation 
of Pol I-mediated rRNA transcription contributes to MYC-
induced proliferation in ovarian epithelial cells, and b) 
MYC-overexpressing human ovarian epithelial cells are 
more sensitive to the anti-proliferative action of the Pol I 
inhibitor CX-5461.
Upregulation of genes involved in both 
mitochondrial rRNA transcription and 
mitoribogenesis contributes to MYC-
induced HFF proliferation
Recent studies in different cell contexts indicate that 
MYC can promote mitochondrial ribogenesis by activating 
Pol II-dependent transcription of the mitochondrial RNA 
polymerase POLRMT and the mitochondrial transcription 
factor TFAM [7, 8]. Further, MYC can induce Pol II-
dependent transcription of several mitoribosome proteins 
(e.g. PTCD3, MRPS5, and MRPS27) [10].
We used the HFF model to assess whether the 
effects of MYC overexpression on proliferation can 
Figure 3: Increased proliferation consequent to upregulation of both “Pol I regulon” genes and rRNA transcription in 
MYC-overexpressing human ovarian epithelial cells. (A-B) Increasing expression of exogenous MYC in IOSE ovarian epithelial 
cells (see qRT-PCR in A, left, and Western Blot in A, right) leads to a MYC dose-dependent upregulation of “Pol I regulon” genes (assessed 
by qRT-PCR) relative to control IOSE cells (B). (C) Exogenous MYC expression in IOSE cells leads to upregulation of rRNA transcription, 
assessed both by pre-rRNA qRT-PCR (left) and quantification of EU incorporation into the B23-positive nucleolar compartment (middle 
and left). Nucleolar EU incorporation was digitally quantified with Photoshop (see Materials and Methods for details). (D) Exogenous 
MYC expression promotes IOSE proliferation, as shown by both MTT assay (left) and EdU incorporation (middle and right). **p<0.01, 
***p<0.001.
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Figure 4: Additional evidence that upregulation of “Pol I regulon” genes contributes to promote cell proliferation 
in MYC-overexpressing IOSE cells. (A-B) Decreasing the level of exogenous MYC in IOSE-MYC2 cells by transient siRNA (see 
qRT-PCR in A, left) is sufficient to significantly decrease the transcript levels of RRN3, UBF, and pre-rRNA (see qRT-PCR in A, right) as 
well as cell proliferation (see EdU incorporation in B). (C-D) Transient knock down of either RRN3 or UBF in IOSE-MYC2 significantly 
decreases pre-rRNA level (see qRT-PCR in C) and cell proliferation (see EdU incorporation in D). *p<0.05, **p<0.01, ***p<0.001.
Figure 5: MYC overexpression sensitizes human ovarian epithelial cells to the anti-proliferative action of the Pol I 
inhibitor CX-5461. (A) The Pol I inhibitor CX-5461 reduces rRNA transcription (assessed by pre-rRNA qRT-PCR) significantly more 
in IOSE-MYC2 than in IOSE-Ctrl cells. (B-C) Consistently, IOSE-MYC2 are more sensitive than IOSE-Ctrl cells to the anti-proliferative 
action of CX-5461, as shown by both MTT assay (B) and analysis of EdU incorporation by immunofluorescence (C). *p<0.05, **p<0.01, 
***p<0.001.
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be traced to either increased mt-rRNA transcription or 
upregulation of mitoribosome proteins. Relative to HFF-
Ctrl, HFF-MYC cells displayed increased levels of both 
POLRMT and TFAM mRNAs (Figure 6A, left), as well as 
increased levels of three pre-mtRNA regions (Figure 6A, 
middle and right): i) a region within the 12S mitochondrial 
RNA, ii) a region within the 16S mtRNA, and iii) a region 
across the 12S and 16S mt-rRNA. Since the 12S and 
16S RNAs are subsequently spliced out to form mature 
mitochondrial rRNAs, this last region is present only in 
mt-rRNA precursors, thus indirectly reflecting the rate 
of mt-rRNA transcription. In addition, HFF-MYC also 
displayed increased transcript levels of PTCD3, MRPS5, 
and MRPS27 mitoribosome proteins relative to HFF-
Ctrl (Figure 6B), thus confirming that, also in this cell 
context, MYC overexpression can promote mitoribosome 
formation by concomitantly enhancing both mt-rRNA 
transcription and expression of mitochondrial ribosomal 
proteins.
To test the contribution of MYC-induced mt-rRNA 
transcription and mitoribogenesis to MYC-induced 
proliferation, first we treated both HFF-Ctrl and HFF-
MYC cells with 2'-C-methyladenosine (2’-C-MeA), which 
inhibits POLRMT-mediated transcription of mt-rRNA 
[33]. As shown in Figure 6C, treatment with 2’-C-MeA 
(20 μM) significantly inhibited mt-rRNA transcription 
(assessed by qRT-PCR of the 12-16S region of the pre-
mtRNA) in HFF-MYC. Consistently, 2’-C-MeA also 
inhibited HFF-MYC proliferation in a dose-dependent 
fashion (see in Figure 6D, red bars). Moreover, when 
compared to HFF-Ctrl, HFF-MYC clearly displayed 
increased sensitivity to the anti-proliferative action of 
2’-C-MeA (Figure 6D).
Second, we treated both HFF-Ctrl and HFF-MYC 
cells with doxycycline, a tetracycline that targets the 28S 
subunit of mitochondrial ribosomes, which is homologous 
to the 30S subunit of bacterial ribosomes. Doxycycline 
inhibited HFF-MYC proliferation in a dose-dependent 
fashion, and its anti-proliferative effects were significantly 
greater in the HFF-MYC cell context than in the HFF-Ctrl 
cell context (Figure 6E).
These preliminary findings in the HFF model 
showed that: i) MYC-induced mt-rRNA transcription 
and mitoribogenesis contribute to promote HFF-MYC 
proliferation; ii) MYC overexpression sensitizes HFF-
MYC cells to the anti-proliferative action of drugs 
inhibiting either mt-rRNA transcription (2’-C-MeA) or 
mitoribosome function (doxycycline).
MYC-induced upregulation of either mt-rRNA 
transcription or mitoribogenesis in human 
ovarian epithelial cell contexts contributes to 
promote proliferation
We found evidence that, relative to CAOV3 ovarian 
cancer cells, which do not overexpress MYC, CAOV4 
Figure 6: Upregulation of mitochondrial rRNA transcription and mitoribosome proteins contributes to MYC-induced 
HFF proliferation. (A) HFF-MYC, overexpressing exogenous MYC, display upregulation of genes involved in mitochondrial RNA 
transcription (left), as well as increased mitochondrial rRNA levels (right), which were quantified by qRT-PCR of the 12S, 16S, or 12-16S 
regions of pre-mtRNA (see scheme in the middle). (B) HFF-MYC cells also display upregulation of genes encoding the mitochondrial 
ribosomal proteins PTCD3, MRPS5, and MRPS27. (C-D) The POLRMT inhibitor 2’-C-MeA inhibits mitochondrial rRNA transcription 
(assessed by qRT-PCR of the 12-16S mt-rRNA) (C) and cell proliferation (assessed by MTT assay) (D) significantly more in HFF-MYC 
relative to HFF-Ctrl. (E) HFF-MYC are more sensitive than HFF-Ctrl to the antiproliferative action of doxycycline, which inhibits 
mitoribosome function. *p<0.05, **p<0.01, ***p<0.001.
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ovarian cancer cells, which overexpress MYC (see Figure 
2A), display a) upregulation of both MYC-target genes 
involved in mt-rRNA transcription (POLRMT and TFAM) 
and MYC-target genes encoding mitoribosome proteins 
(PTCD3, MRPS5, MRPS27) (Figure 7A) as well as b) 
increased mitochondrial rRNA synthesis (Figure 7B). 
For this reason, we set out to test whether MYC ectopic 
overexpression in human ovarian epithelial cell contexts 
(IOSE and HOSE) leads to increased mt-rRNA synthesis 
and affects mitoribogenesis.
Using the panel of IOSE cells, we detected MYC 
level-dependent upregulation of POLRMT, TFAM, 
PTCD3, MRPS5, and MRPS27 mRNAs (Figure 8A, left), 
as well as increased 12-16S mt-rRNA level (Figure 8A, 
right) in IOSE-MYC and IOSE-MYC2 cells relative to 
IOSE-Ctrl cells. In addition, transient MYC knock down 
in IOSE-MYC2 significantly reduced both POLRMT 
and 12-16S mt-rRNA transcript levels (Figure 8B). In 
turn, POLRMT knock down in IOSE-MYC2 decreased 
both mt-rRNA transcription (Figure 8C, left) and cell 
proliferation (assessed by EdU incorporation, Figure 8C, 
middle and right). Similar findings were obtained in the 
HOSE cell context (Supplementary Figure 2A-2B).
Apparently, MYC ectopic overexpression 
in different human ovarian epithelial cell contexts 
promotes mt-rRNA transcription and mitoribogenesis 
by upregulating MYC-target genes that are involved in 
these two processes. Moreover, MYC-induced mt-rRNA 
transcription and mitoribogenesis contribute to MYC-
induced cell proliferation.
Antiproliferative effect of 2’-C-MeA and 
doxycycline, alone or in combination with 
CX-5461, on MYC overexpressing ovarian 
epithelial cells
Recently, it was reported that selective inhibition of 
either mt-rRNA transcription or mitoribosome function 
exerts an antiproliferative effect on MYC-overexpressing 
cancer cells [7, 10].
First, we found by MTT assay that IOSE-MYC2, 
relative to IOSE-Ctrl cells (Figure 9A), display increased 
sensitivity to the antiproliferative action of the POLRMT 
inhibitor 2’-C-MeA. Similar findings were also obtained 
in HOSE-MYC relative to HOSE-Ctrl (Supplementary 
Figure 2C). The 2’-C-MeA concentration of 40 μM, which 
determined the most significant difference between IOSE-
MYC2 and IOSE-Ctrl proliferation in the MTT assay, 
also decreased 12-16S mt-rRNA transcription (Figure 
9B) and the number of cells in S phase (assessed by EdU 
incorporation) (Figure 9C) significantly more in IOSE-
MYC2 versus IOSE-Ctrl proliferation. Moreover, when 
we tested the effect of 40 μM 2’-C-MeA in combination 
with CX5461 (ranging from 5 nM to 100 nM) in IOSE-
MYC2 cells, we found that 2’-C-MeA significantly 
enhanced the antiproliferative effect of CX-5461 low 
concentrations (5-10 nM) (Figure 9D).
Second, by MTT assay we found that IOSE-MYC2 
versus IOSE-Ctrl (Figure 10A, left), as well as HOSE-
MYC versus HOSE-Ctrl (Supplementary Figure 2D), 
displayed increased sensitivity to the anti-proliferative 
action of doxycycline across a range of concentrations (0-
25 μM). The doxycycline concentration of 15 μM showed 
the most significant difference between IOSE-MYC2 and 
IOSE-Ctrl proliferation both in the MTT assay (Figure 
10A, left) and in the EdU incorporation assay (Figure 10A, 
right). Remarkably, when we tested the effect of 15 μM 
doxycycline in combination with CX5461 (ranging from 
5 nM to 100 nM) on IOSE-MYC2 cells, we found that 
doxycycline significantly enhanced the antiproliferative 
effect of CX-5461 at concentrations between 5 and 25 nM 
(Figure 10B).
Apparently, MYC-overexpression sensitized ovarian 
epithelial cells to both 2’-C-MeA and doxycycline, 
which target, respectively, mt-rRNA transcription and 
mitoribosome function. Moreover both 2’-C-MeA and 
Figure 7: Evidence that MYC overexpression in ovarian cancer cells is associated with upregulation of genes involved 
in mitochondrial rRNA transcription and ribogenesis. (A-B) qRT-PCR showing that CAOV4 ovarian cancer cells, which 
overexpress endogenous MYC, display upregulation of genes involved in mitochondrial rRNA transcription (A, left) and ribogenesis (A, 
right) as well as increased levels of 12S, 16S, and 12-16S mitochondrial rRNA (B) relative to CAOV3 cells, which do not overexpress 
MYC. All differences between CAOV4 and CAOV3 are significant (p<0.05).
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Figure 8: MYC-induced upregulation of mitochondrial rRNA transcription and ribogenesis contributes to promote 
proliferation of human ovarian epithelial cells. (A) qRT-PCR showing MYC dose-dependent upregulation of genes involved in 
mitochondrial rRNA transcription and ribogenesis (left) as well as 12-16S mt-rRNA (right) in IOSE-MYC and IOSE-MYC2 cells relative 
to IOSE-Ctrl. (B) Transient MYC knock down by siRNA significantly reduces both POLRMT and mt-rRNA transcription (assessed by 12-
16S mt-rRNA qRT-PCR) in IOSE-MYC2. (C) Transient POLRMT knock down in IOSE-MYC2 cells, by reducing mt-rRNA transcription 
(left), leads to decreased proliferation (assessed by EdU incorporation) (middle and right). *p<0.05, **p<0.01, ***p<0.001.
Figure 9: MYC overexpression sensitizes human ovarian epithelial cells to the anti-proliferative action of 2’-C-MeA, 
alone or in combination with CX-5461. (A) 2’-C-MeA inhibits cell proliferation (assessed by MTT assay) significantly more in 
IOSE-MYC2 that IOSE-Ctrl. (B-C) 2’-C-MeA (40 μM) reduces both mt-rRNA transcription (assessed by qRT-PCR of 12-16S mt-rRNA) 
(B) and the number of cells in S phase (assessed by EdU incorporation) (C) significantly more in IOSE-MYC2 than in IOSE-Ctrl cells. 
(D) MTT assay showing that 2’-C-MeA (40 μM) significantly enhances the antiproliferative effect of CX-5461 (5-10 nM) in IOSE-MYC2 
cells. *p<0.05, **p<0.01, ***p<0.001.
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doxycycline potentiated the antiproliferative effect of 
low doses of the CX-5461 inhibitor of Pol I-mediated 
nucleolar rRNA transcription.
Both 2’-C-MeA and doxycycline can enhance the 
antiproliferative effects of CX-5461 in MYC-
overexpressing ovarian cancer cells
In this study we found that CAOV4 ovarian cancer 
cells overexpressing endogenous MYC show upregulation 
of nucleolar rRNA and “Pol I regulon” genes (Figure 2) 
as well as increased mitochondrial rRNA transcription 
and upregulation of MYC-target genes involved in 
mitochondrial rRNA transcription and ribogenesis (Figure 
7). Dose-dependent inhibition of Pol I-mediated rRNA 
transcription with CX-5461 (Figure 11A, left) significantly 
reduced CAOV4 cell proliferation (Figure 11A, right). 
Treatment with either 2’C-MeA (Figure 11B, left) or 
doxycycline (Figure 11B, right) also led to dose-dependent 
inhibition of CAOV4 cell proliferation. Moreover, the 
anti-proliferative effects of CX-5461 on CAOV4 was 
significantly enhanced by co-treatment with either 
2’C-MeA (80 or 160 μM, Figure 11C) or doxycycline (15 
or 25 μM, Figure 11D), which were among the lowest 
concentrations able to induce significant inhibition of 
CAOV4 proliferation. In conclusion, combining CX-5461 
with drugs inhibiting either mt-rRNA transcription (e.g. 
2’C-MeA) or mitoribosome function (e.g. doxycycline) 
seems to be an effective antiproliferative strategy to treat 
MYC-overexpressing ovarian cancer.
DISCUSSION
Increasing knowledge of MYC-coordinated 
regulation of functions involved in both nucleolar and 
mitochondrial rRNA transcription and ribogenesis 
can open new avenues to treat MYC-driven cancer. In 
this study, we provide evidence of the added value of 
pharmacological targeting mitochondrial POLRMT-
mediated mt-rRNA transcription or mitoribosome 
translational function in conjunction with a well-
established inhibitor of nucleolar Pol I-mediated rRNA 
transcription in MYC-overexpressing (cancer) cells 
(Figure 12).
Evidence that nucleolar rRNA transcription and 
ribogenesis are frequently upregulated in cancer due to 
different etiological factors has led to the development of 
novel small molecules capable of inhibiting Pol I [15, 19, 
Figure 10: MYC overexpression sensitizes human ovarian epithelial cells to the anti-proliferative action of doxycycline, 
alone or in combination with CX-5461. (A) Doxycycline inhibits cell proliferation (assessed both by MTT assay, shown on the left, 
and EdU incorporation assay, shown on the right) significantly more in IOSE-MYC2 than in IOSE-Ctrl. (B) MTT assay showing that 
doxycycline (15 μM) significantly enhances the antiproliferative effect of CX-5461 (5-25 nM) in IOSE-MYC2 cells. *p<0.05, **p<0.01, 
***p<0.001.
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34, 35]. In particular, one of these molecules, CX-5461, 
which targets Pol I-mediated rRNA transcription, proved to 
be effective in in vitro and preclinical MYC-driven cancer 
cell models [16, 21, 22]. CX-5461 is currently tested in 
clinical trials for advanced hematological malignancies 
(Australian New Zealand Clinical Trials Registry 
12613001061729) and solid tumors (ClinicalTrials.gov 
Identifier NCT02719977), and its use could be extended 
to clinical trials of MYC-driven solid tumors, including 
breast, ovarian and prostate cancer [19, 24, 32].
Interestingly, CX-5461 was shown to be even 
more effective when used in combination with other 
drugs, such as drugs targeting PI3K-AKT-mTORC1-
dependent nucleolar ribosome biogenesis and translation 
[21]. By the same tenet, we reasoned that CX-5461 could 
also be more effective if combined with drugs targeting 
mitochondrial ribogenesis processes and translation 
in MYC-overexpressing cells. Indeed, recent studies 
highlighted the anticancer potential of several antiviral 
and antibacterial molecules capable of targeting either 
POLRMT-mediated mitochondrial rRNA transcription or 
mitoribosome function [7, 10, 26]. Specifically, there are 
several ribonucleosides analogues, originally developed 
for antiviral therapy, which are substrates and inhibitors of 
human mitochondrial RNA polymerase (POLRMT) [33], 
and can be repurposed for cancer therapy. In preclinical 
studies the 2-C-methyladenosine ribonucleoside 
(2’-C-MeA) was shown to reduce mitochondrial gene 
expression and increase cell death in acute myelogenous 
leukemia (AML), while treatment of normal human 
Figure 11: Both 2’-C-MeA and doxycycline can enhance the antiproliferative effects of CX-5461 in MYC-overexpressing 
ovarian cancer cells. (A) CX-5461, by inhibiting Pol I-mediated rRNA transcription (assessed by pre-rRNA qRT-PCR, left), significantly 
hinders the proliferation of MYC-overexpressing CAOV4 ovarian cancer cells (assessed by MTT assay, right). (B) Both inhibition of mt-
rRNA transcription by 2’C-MeA (left) and inhibition of mitoribosome function by doxycycline (right) significantly decrease CAOV4 cell 
proliferation. (C-D) Both 2’-C-MeA (C) and doxycycline (D) enhance the antiproliferative effects of CX-5461 in CAOV4 cells. *p<0.05, 
**p<0.01, ***p<0.001.
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hematopoietic cells did not alter clonogenic growth [27]. 
Due to the ancestral relationship between bacteria and 
mitochondria, several classes of antibiotics, including 
tetracyclines (e.g. Doxycycline and Tigecycline) capable 
of targeting mitoribosome function, are also re-evaluated 
as potential anti-cancer drugs ([26] and references within).
This study provides the proof of concept that 
available drugs targeting mitochondrial ribogenesis 
or mitoribosome function can improve the anticancer 
effects of emerging new drugs capable of selectively 
targeting nucleolar Pol I rRNA synthesis in cancer and, in 
particular, MYC-driven cancer of different histotypes due 
to concomitant MYC deregulation of both nucleolar and 
mitochondrial rRNA synthesis and ribogenesis processes.
Based on preliminary observations that ovarian 
cancer cells overexpressing MYC (CAOV4) displayed 
upregulation of POLRMT and mt-rRNA synthesis 
relative to ovarian cancer cells that do not overexpress 
MYC (CAOV3), we assessed the antiproliferative effects 
of targeting POLRMT-mediated mt-rRNA transcription 
in two human ovarian epithelial cell contexts (IOSE and 
HOSE), and in human fibroblasts (HFF) overexpressing 
MYC. Consistent with genetic studies (either MYC or 
POLRMT knock down), we found that the POLRMT 
inhibitor 2’-C-MeA significantly reduced both mt-
rRNA transcription and the number of cells in S phase. 
Remarkably, even if MYC-overexpressing ovarian 
epithelial cells were more sensitive to the anti-proliferative 
action of the Pol I inhibitor CX-5461 alone, 2’-C-MeA 
significantly enhanced the effects of CX-5461. Indeed, 
in the presence of 2’-C-MeA, CX-5461 exerted an anti-
proliferative effect at lower concentrations (5-10 nM).
Further, based on the fact that MYC upregulation 
induces PTCD3, MRPS5, and MRPS27 proteins necessary 
for mitoribogenesis in MYC-overexpressing CAOV4 
cancer cells, as well as in HFF fibroblast and different 
ovarian epithelial cell contexts with MYC overexpression, 
we tested if doxycycline, a tetracycline that targets the 
28S subunit of mitochondrial ribosomes, was capable 
of reducing MYC-induced proliferation. Indeed, we 
found that MYC-overexpressing fibroblasts and ovarian 
epithelial cells were more sensitive than control cells 
to the anti-proliferative action of doxycycline alone. 
Moreover, doxycycline, when used in combination with 
Figure 12: Targeting nucleolar and mitochondrial rRNA transcription and ribogenesis to curb MYC-induced cancer 
cell proliferation. MYC can promote nucleolar rRNA transcription by directly activating Pol I-mediated transcription of ribosomal genes, 
as well as by upregulating Pol II-mediated transcription of “Pol I regulon” genes. Concomitantly, MYC can also promote mitoribosome 
synthesis by upregulating Pol II-mediated transcription of genes encoding factors necessary for mitochondrial rRNA transcription 
(POLRMT and TFAM) and mitochondrial ribosomal proteins (PTCD3, MRPS5, and MRPS27). Drugs inhibiting Pol I (e.g. CX-5461), 
mitochondrial rRNA transcription (e.g. 2’-C-MeA), or mitoribosome function (e.g. doxycycline) could be used, alone or in combination, to 
target MYC-overexpressing cancer cells, such as ovarian cancer cells.
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low doses of CX-5461 Pol I inhibitor, enhanced CX-5461 
antiproliferative effect in MYC overexpressing ovarian 
epithelial cells. In the same cell contexts, we also tested 
Tigecycline, another tetracycline that was recently shown 
to curb proliferation of MYC-overexpressing lymphoma 
and osteosarcoma cells [7, 10], but we did not achieve the 
anti-proliferative effects of doxycycline (data not shown).
Finally, we found that CX-5461 significantly 
inhibits CAOV4 ovarian cancer cell proliferation, and that 
the anti-proliferative effect of CX-5461 is significantly 
enhanced by co-treatment with either 2’C-MeA or 
doxycycline. Since CX-5461 was recently shown to have 
a positive effect on both chemoresistant ovarian epithelial 
cells and patient derived xenografts [36], it is possible 
that drugs targeting mt-rRNA and mitoribogenesis, when 
combined with drugs inhibiting Pol I like CX-5461, can 
be also effective in chemoresistant MYC-overexpressing 
cancer cell populations.
Overall these findings indicate that leveraging a) 
MYC-regulated rRNA transcription by RNA polymerases 
in distinct cell sites (nucleolar Pol I and mitochondrial 
POLRMT) and b) other MYC-regulated processes and 
functions of ribogenesis and mitoribogenesis, can be an 
offbeat approach to control MYC-driven cancers.
MATERIALS AND METHODS
Cells and cell culture
HFF-Ctrl (originally named HFF-pB) and HFF-
MYC human foreskin fibroblast cell lines, kindly 
obtained from Dr. C. Grandori, Fred Hutchinson Cancer 
Research Center, Seattle, and previously described in 
[3, 28], were grown in DMEM plus 10% FBS (Thermo 
Fisher). CAOV3 and CAOV4 ovarian cancer cells (both 
from ATCC, Manassas, VA) were grown in DMEM plus 
10% FBS and MCDB105/Media199 1:1 plus 15% FBS, 
respectively. Telomerase-immortalized human ovarian 
surface epithelial cells (IOSE, clone C21), kindly provided 
by Dr. F. Balkwill, Barts Cancer Institute, Queen Mary 
University of London, London, were grown in MCDB105/
Media199 1:1 plus 15% FBS supplemented with 5 μg/ml 
insulin (Sigma), 10 ng/ml human EGF (Peprotech), 0.5 
μg/ml hydrocortisone (Sigma), and 34 μg protein/ml BPE 
(Lonza) [31]. T1074 SV40-immortalized human ovarian 
epithelial cells (in this study referred to as HOSE) were 
purchased from ABM (Richmond, BC, Canada) and 
grown in MCDB105/Media199 1:1 plus 15% FBS. All 
cell lines were grown in a humidified incubator with 5% 
CO2 at 37°C.
IOSE cells stably overexpressing different levels 
of ectopic MYC (IOSE-MYC and IOSE-MYC2) were 
developed by lentiviral infection. First, human MYC 
cDNA was subcloned from pCDH-puro-MYC (Addgene) 
into the BamH I/Xba I restriction sites of pCDH-Hygro 
(CD515B-1) (System Biosciences). Second, pCDH-
Hygro-MYC was co-transfected along with VSV-G 
and DeltaR plasmids (both provided by Dr. K. Gurova, 
Roswell Park Cancer Institute, Buffalo, NY) into HEK293 
cells by using lipofectamine LTR (Thermo Fisher) in 
order to produce lentiviral particles. Medium containing 
lentiviral particles was harvested after 48h and 72h 
and filtered through a 0.45 μ filter. Lentiviral titer was 
assessed by using Lenti-X Go Stix (Clontech). Finally, 
40-50% confluent IOSE cells were infected with medium 
containing lentiviral particles diluted 1:2 (IOSE-MYC2) or 
1:3 (IOSE-MYC) with growth medium, in the presence of 
polybrene at a final concentration of 8 μg/ml. The infection 
was repeated after 24h. After two rounds of infection, cells 
were trypsinized, seeded in flasks and selected with 0.2 
mg/ml hygromycin. In parallel, IOSE were infected with 
empty pCDH-Hygro to obtain IOSE-Ctrl cells. HOSE 
stably overexpressing ectopic MYC (HOSE-MYC2) were 
developed by lentiviral infection as described above using 
pCDH-puro-MYC for lentiviral production and using 
puromycin (0.5 μg/ml) for selection. Control HOSE were 
developed by infection with empty pCDH-puro. HFF-pB 
and HFF-MYC were authenticated by PCR detection of 
pBABE and pBABE-MYC, respectively. IOSE and HOSE 
were fingerprinted by STR analysis.
Drugs and treatments
CX-5461 (ApexBio) was dissolved in 50 mM 
NaH2PO4 (pH 4.5) to obtain a 1 mM stock solution. 
2’-C-Methyladenosine (Santa Cruz Biotechnologies) 
was dissolved in DMSO to obtain a 100 mM stock 
solution. Doxycycline (Fisher Scientific) was dissolved 
in H2O to obtain a 100 mM stock solution. Drugs were 
stored in aliquots at -20°C. Treatments were performed 
with drugs or vehicle diluted in medium at the indicated 
concentrations as described in the Results. For qRT-PCR 
analysis, EU incorporation, and EdU incorporation, 30-
50% confluent cells were treated for 24 h. For MTT 
analysis, cells were treated for 3-5 days refreshing the 
medium every 48 hours for the duration of the treatment.
siRNA
40-60% confluent cells seeded on 24-well plates 
were transiently transfected with 10 nM Silencer 
Select pre-designed siRNAs (Thermo Fisher) targeting 
MYC (s9129+s9131), UBTF (s14613+s14615), RRN3 
(s29324) or POLRMT (s10825+s10826) by using RNAi 
max Lipofectamine (Thermo Fisher) according to the 
manufacturer’s instructions. As a negative control, cells 
were transfected with 10 nM siRNA Negative Control 
(Thermo Fisher). 24-48h after transfection, cells were 
analyzed by qRT-PCR or EdU incorporation.
Western blot
Cells were lysed in RIPA Buffer (Cell Signaling) 
supplemented with 1 mM PMSF and EDTA-free Protease 
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Inhibitor Cocktail (Roche). Total protein concentration 
was measured by using Coomassie Plus Protein Assay 
Reagent (Thermo Fisher). Equal amounts of proteins 
were separated by SDS PAGE electrophoresis and 
transferred onto a PVDF membrane according to standard 
procedures. Membranes were blocked with 5% non-fat dry 
milk diluted in TBS + 0.05% Tween 20 for 1 h at room 
temperature, incubated over night at 4 °C with anti-MYC 
(C33) antibody (Santa Cruz Biotechnology) diluted in 5% 
milk, washed, incubated for 1 h at room temperature with 
HRP-conjugated anti-mouse antibody (GE Healthcare) 
diluted in 5% milk, washed, and incubated with Clarity 
Western ECL Substrate (Bio-Rad). Chemiluminescence 
was detected and quantified by using ChemiDoc Touch 
Imaging System (Bio-Rad).
qRT-PCR
RNA was extracted with Trizol (Thermo Fisher), 
treated with DNase I (Thermo Fisher), and retrotranscribed 
by using High Capacity cDNA reverse transcription kit 
(Thermo Fisher). cDNA was analyzed by real time PCR by 
using the iQ SYBR Green Supermix (Bio-Rad) and primers 
amplifying MYC (sense: 5′-cctctcaacgacagcagct-3′, 
antisense: 5′-cagaaggtgatccagactctg-3′), pre-rRNA 
5’ETS (sense: 5′-CTGAGGGAGCTCGTCGGTGT-3′, 
antisense: 5′-GCAGAGCGCCTCCGAAGTCA-3′), UBF 
(sense: 5′-ACCAAGCCACCTCCGAACAG-3′, antisense: 





(sense: 5′-TGCCACAGGGCCATCATCAC-3′, antisense: 
5′-CATGGAGGCCCTTCTTATCAG-3′), MRPS27 (sense: 
5′-GGCTATGCACTTCTTGGGAAG-3′, antisense: 5′-GC 
ACATCGAGCGCTTCTCTAC-3′), TAF1C (5′-GGACA 
GGCTGCATTTCCAAGAG-3′, antisense: 5′-AGGTGA 
GGGCTGAGGCTGAT-3′), POLR1B (5′-TATGGAAG 
ATGCCATGATTGTGA-3′, antisense: 5′-TGTAATACG 
GATCTCCGTACTG-3′), POLR1E (sense: 5′-GGTGT 
GACTGCTCTGGTCAG-3′, antisense: 5′-GGTGCAAT 
GGCTGTTCTCCTC-3′), POLRMT (sense: 5′-CATCG 
AAAGGTGTCTGGAACAG-3′, antisense: 5′-CACGCC 
CATCCTTGGCATAC-3′), TFAM (sense: 5′-CATCTG 
TCTTGGCAAGTTGTCC-3′, antisense: 5′-ACTCCGC 
CCTATAAGCATCTTG-3′), mtRNA 12S (sense: 
5′-GTGAGTTCACCCTCTAAATCAC-3′, antisense: 
5′-GACTTGGGTTAATCGTGTGACC-3′), mtRNA 16S 
(sense: 5′-CCTGGTGATAGCTGGTTGTCC-3′, antisense: 
5′-CAATTGGGTGTGAGGAGTTCAG-3′), mtRNA 12-
16S (sense: 5′-GAGGAGACAAGTCGTAACATGG-3′, 
antisense: 5′-CTATATCTATTGCGCCAGGTTTC-3′), or 
GAPDH (sense: 5′-GAAGGTGAAGGTCGGAGTC-3′, 
antisense: 5′-GAAGATGGTGATGGGATTTC-3′) as we 
previously described [20]. Statistical significance was 
calculated by using the Student’s t-test.
Assessment of nucleolar EU incorporation
5-ethynyl uridine (EU) incorporation assay was 
performed by using Click-iT RNA Alexa Fluor Imaging 
Kit (Thermo Fisher). Subconfluent cells were incubated 
with 1 mM EU under standard growth conditions for 
2 h, fixed with 4% paraformaldehyde for 10 min., 
permeabilized with PBS + 0.5 % Triton X100 for 15 
min. and incubated with Click-iT reaction cocktail for 30 
min., blocked with PBS+ (PBS plus 1% BSA, 1% FBS, 
0.05% Tween 20) for 20 min, incubated with anti-B23 
(Santa Cruz) diluted in PBS+ for 1 h at room temperature, 
washed four times with PBS+, incubated with anti-
rabbit AlexaFluor 546 (Thermo Fisher) diluted in PBS+ 
for 1 h, washed four times with PBS, counterstained 
with 330 nM DAPI for 10 min., and mounted with 
Vectashield (Vector Laboratories). Cells were imaged 
with a fluorescence microscope using the same exposure 
time for each fluorescent channel. EU incorporation in 
the nucleolar compartment (identified by B23 staining) 
was assessed with Adobe Photoshop by multiplying the 
EU-positive nucleolar area (number of pixels) by the 
EU signal intensity (mean) in the B23-positive nucleolar 
compartment normalized to the EU signal intensity (mean) 
in the surrounding nucleoplasm. Statistical significance 
was calculated by Student’s t-test.
MTT assay
2-5 x 103 cells/well were seeded in 24-well plates 
in four replicates, let attach overnight, and treated with 
the indicated drugs diluted in growth medium. After 
3-5 days of treatment, cells were incubated for 2 hours 
under standard growth conditions with 0.5 mg/ml 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (Sigma) and lysed with DMSO. Cell 
lysates were transferred into a 96- well plate, and 
absorbance at 570 nm was measured on a microplate 
spectrophotometer. Statistical significance was calculated 
by Student’s t-test.
EdU incorporation assay
EdU-incorporation was assessed with Click-iT 
EdU imaging kit (Thermo Fisher), according to the 
manufacturer’s instructions. Briefly, cells were incubated 
under standard growth conditions with 10 μM EdU for 
1h. After EdU incorporation, cells were fixed with 4% 
paraformaldehyde for 10 min., incubated with PBS plus 
0.5 % Triton X100 for 10 min., washed with PBS plus 
3% BSA, reacted with Click-iT reaction cocktail for 30 
min., counterstained with 330 nM DAPI for 10 min, and 
mounted with Vectashield (Vector Laboratories). Cells 
were imaged with a fluorescence microscope. DAPI-
positive cells and EdU-positive cells were counted in 
at least 5 random fields. Statistical significance was 
calculated by using the Student’s t-test.
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